New drug cocktail aims to stop bile duct cancer from returning after surgery
NCT ID NCT04669496
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether giving a combination of an immunotherapy drug (toripalimab), a targeted therapy (lenvatinib), and chemotherapy (GEMOX) before surgery can improve outcomes for people with a high-risk type of bile duct cancer. The trial includes 178 patients whose cancer is removable but has features that make it likely to come back. The goal is to see if this pre-surgery treatment can delay or prevent recurrence and extend survival compared to surgery alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Toripalimab (PD-1 antibody), lenvatinib, and GEMOX chemotherapy
- What this could lead to
- If successful, this combination given before surgery could lower the chance of bile duct cancer coming back and improve long-term survival for high-risk patients.
- What could go wrong
- This is an early-to-mid stage trial with only 178 participants, so results may not apply to everyone. The drug combo can cause significant side effects, and it's not yet proven to be better than standard surgery alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEMOX CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan hospital
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a Triple-Drug combo outsmart a rare and aggressive cancer?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- Can matching drugs to tumor genes beat biliary cancer?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?